These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31565661)

  • 1. Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population.
    Montecillo-Aguado MR; Montes-Gómez AE; García-Cordero J; Corzo-Gómez J; Vivanco-Cid H; Mellado-Sánchez G; Muñoz-Medina JE; Gutiérrez-Castañeda B; Santos-Argumedo L; González-Bonilla C; Cedillo-Barrón L
    J Immunol Res; 2019; 2019():7239347. PubMed ID: 31565661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
    Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
    J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology.
    Priyamvada L; Hudson W; Ahmed R; Wrammert J
    Emerg Microbes Infect; 2017 May; 6(5):e33. PubMed ID: 28487557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Anti-Dengue and Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing.
    Rojas A; Natrajan MS; Weber J; Cardozo F; Cantero C; Ananta JS; Kost J; Tang M; López S; Bernal C; Guillén Y; Mendoza L; Páez M; Pinsky BA; Waggoner JJ
    Am J Trop Med Hyg; 2021 Mar; 104(5):1729-1733. PubMed ID: 33782214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
    Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
    mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
    Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
    Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.
    Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK
    J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of Flavivirus Neutralizing Antibodies in Thailand by High-Throughput Neutralization Assay: Endemic Circulation of Zika Virus before 2012.
    Yamanaka A; Matsuda M; Okabayashi T; Pitaksajjakul P; Ramasoota P; Saito K; Fukasawa M; Hanada K; Matsuura T; Muramatsu M; Shioda T; Suzuki R
    mSphere; 2021 Aug; 6(4):e0033921. PubMed ID: 34259560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey on neutralizing antibodies against Zika virus eighteen months post-outbreak in two southern Thailand communities.
    Densathaporn T; Sangthong R; Sakolnapa M; Surasombatpattana S; Kemapunmanus M; Masrinoul P; Yoksan S; McNeil EB; Chongsuvivatwong V
    BMC Infect Dis; 2020 Dec; 20(1):921. PubMed ID: 33272192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
    Dejnirattisai W; Supasa P; Wongwiwat W; Rouvinski A; Barba-Spaeth G; Duangchinda T; Sakuntabhai A; Cao-Lormeau VM; Malasit P; Rey FA; Mongkolsapaya J; Screaton GR
    Nat Immunol; 2016 Sep; 17(9):1102-8. PubMed ID: 27339099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection.
    Collins MH; McGowan E; Jadi R; Young E; Lopez CA; Baric RS; Lazear HM; de Silva AM
    Emerg Infect Dis; 2017 May; 23(5):773-781. PubMed ID: 28418292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue Virus and Zika Virus Serological Cross-reactivity and Their Impact on Pathogenesis in Mice.
    Watanabe S; Tan NWW; Chan KWK; Vasudevan SG
    J Infect Dis; 2019 Jan; 219(2):223-233. PubMed ID: 30085051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?
    Gunawardana SA; Shaw RH
    BMC Infect Dis; 2018 Dec; 18(1):641. PubMed ID: 30526531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.
    Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM
    J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An epidemiological survey of the current status of Zika and the immune interaction between dengue and Zika infection in Southern Taiwan.
    Wang WH; Urbina AN; Wu CC; Lin CY; Thitithanyanont A; Assavalapsakul W; Lu PL; Chen YH; Wang SF
    Int J Infect Dis; 2020 Apr; 93():151-159. PubMed ID: 31982624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human antibody response to Zika targets type-specific quaternary structure epitopes.
    Collins MH; Tu HA; Gimblet-Ochieng C; Liou GA; Jadi RS; Metz SW; Thomas A; McElvany BD; Davidson E; Doranz BJ; Reyes Y; Bowman NM; Becker-Dreps S; Bucardo F; Lazear HM; Diehl SA; de Silva AM
    JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue immune sera enhance Zika virus infection in human peripheral blood monocytes through Fc gamma receptors.
    Li M; Zhao L; Zhang C; Wang X; Hong W; Sun J; Liu R; Yu L; Wang J; Zhang F; Jin X
    PLoS One; 2018; 13(7):e0200478. PubMed ID: 30044839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.